RxDoctor Payments Data

Amy Raetz-Benner, NP

Acute Care · Midland, MINPI 1649745019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Abiomed at 33.3% of the total. Reporting peaked in 2022 at $698 and has fallen 72.4% since, to $192 in 2025. Among acute care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,433in general payments, 2019–2025

Across 95 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$811
  • Johnson & Johnson$387
  • Kestra Medical Technology Services, Inc.$273
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$265
  • Abbott$229
  • Novartis$207
  • plus $261 from 5 others

What the payments were for

  • Food & beverage$2,433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,433 in reported general payments places this provider in the 90th percentile of 567 acute care providers in Michigan.

See all acute care providers in Michigan

Medicare billing

Part B allowed, 2024
$29,632
Medicare patients
185
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan154$172,009
JardianceEmpagliflozin78$95,900
FarxigaDapagliflozin Propanediol98$92,159
EliquisApixaban15$16,000
Potassium Chloride169$7,709
Bumetanide131$7,263
Torsemide138$4,501
Spironolactone318$2,498
Bisoprolol Fumarate81$2,038
Furosemide373$1,997
Metoprolol Succinate131$1,826
Eplerenone41$1,750
Midodrine Hcl11$1,093
Hydralazine Hcl57$1,007
Losartan Potassium51$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$207$172,009154 claims
AstraZenecaFarxiga$76$92,15998 claims
PfizerEliquis$38$16,00015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 acute care providers in Michigan.

Other acute care in Midland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →